A R Zolopa

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. doi request reprint A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results
    Andrew Zolopa
    Division of Infectious Diseases and Geographic Medicine, Stanford University, Palo Alto, CA 94305, USA
    J Acquir Immune Defic Syndr 63:96-100. 2013
  2. doi request reprint Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial
    Andrew R Zolopa
    Div of Infectious Diseases and Geographic Medicine, Stanford University, 300 Pasteur Dr, Rm S 156 GrantBldg, Stanford, CA 94305, USA
    J Infect Dis 201:814-22. 2010
  3. doi request reprint The evolution of HIV treatment guidelines: current state-of-the-art of ART
    Andrew R Zolopa
    Division of Infectious Diseases and Geographic Medicine, Stanford University, Palo Alto, CA 94305, USA
    Antiviral Res 85:241-4. 2010
  4. pmc Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial
    Andrew Zolopa
    Stanford University AIDS Clinical Trials Unit, Stanford University, Stanford, California, United States of America
    PLoS ONE 4:e5575. 2009
  5. ncbi request reprint Incorporating drug-resistance measurements into the clinical management of HIV-1 infection
    Andrew R Zolopa
    Department of Medicine, Stanford University, Palo Alto, CA 94304, USA
    J Infect Dis 194:S59-64. 2006
  6. pmc HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed
    A R Zolopa
    Division of Infectious Diseases and Geographical Medicine, Stanford University School of Medicine, CA 94305, USA
    Ann Intern Med 131:813-21. 1999
  7. ncbi request reprint Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study)
    Andrew R Zolopa
    Stanford University School of Medicine, Stanford, CA 94305 5107, USA
    Clin Infect Dis 41:92-9. 2005
  8. ncbi request reprint Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response
    N S Shulman
    Stanford University School of Medicine, Division of Infectious Diseases, California 94305, USA
    J Acquir Immune Defic Syndr 23:221-6. 2000
  9. pmc High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients
    R W Shafer
    Division of Infectious Diseases and Center for AIDS Research, Stanford University Medical Center, Stanford, California 94305, USA
    J Clin Microbiol 39:1522-9. 2001
  10. ncbi request reprint Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy
    N Shulman
    Stanford University School of Medicine, Stanford, CA 94305, USA
    AIDS 15:1125-32. 2001

Research Grants

  1. Stanford AIDS Clinical Trials Unit
    Andrew Zolopa; Fiscal Year: 2007

Detail Information

Publications37

  1. doi request reprint A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results
    Andrew Zolopa
    Division of Infectious Diseases and Geographic Medicine, Stanford University, Palo Alto, CA 94305, USA
    J Acquir Immune Defic Syndr 63:96-100. 2013
    ..9% to 8.3%). Discontinuation due to adverse events was low (5% vs 7%). Median changes in serum creatinine (mg/dL) at week 96 were similar to week 48. These results support the durable efficacy and long-term safety of EVG/COBI/FTC/TDF...
  2. doi request reprint Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial
    Andrew R Zolopa
    Div of Infectious Diseases and Geographic Medicine, Stanford University, 300 Pasteur Dr, Rm S 156 GrantBldg, Stanford, CA 94305, USA
    J Infect Dis 201:814-22. 2010
    ....
  3. doi request reprint The evolution of HIV treatment guidelines: current state-of-the-art of ART
    Andrew R Zolopa
    Division of Infectious Diseases and Geographic Medicine, Stanford University, Palo Alto, CA 94305, USA
    Antiviral Res 85:241-4. 2010
    ..This article forms part of a special issue of Antiviral Research marking the 25th anniversary of antiretroviral drug discovery and development, vol. 85, issue 1, 2010...
  4. pmc Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial
    Andrew Zolopa
    Stanford University AIDS Clinical Trials Unit, Stanford University, Stanford, California, United States of America
    PLoS ONE 4:e5575. 2009
    ..Optimal timing of ART initiation for individuals presenting with AIDS-related OIs has not been defined...
  5. ncbi request reprint Incorporating drug-resistance measurements into the clinical management of HIV-1 infection
    Andrew R Zolopa
    Department of Medicine, Stanford University, Palo Alto, CA 94304, USA
    J Infect Dis 194:S59-64. 2006
    ..Finally, newer indicators, such as replication capacity, are clinically available and appear to have prognostic value, but how this in vitro measure should be used in the management of antiretroviral therapy remains to be fully defined...
  6. pmc HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed
    A R Zolopa
    Division of Infectious Diseases and Geographical Medicine, Stanford University School of Medicine, CA 94305, USA
    Ann Intern Med 131:813-21. 1999
    ..Tests for resistance to HIV drugs are available for clinical use; however, their predictive value has not been fully assessed...
  7. ncbi request reprint Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study)
    Andrew R Zolopa
    Stanford University School of Medicine, Stanford, CA 94305 5107, USA
    Clin Infect Dis 41:92-9. 2005
    ..We sought to determine how much agreement exists within a group of experts in the interpretation of complex genotypes...
  8. ncbi request reprint Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response
    N S Shulman
    Stanford University School of Medicine, Division of Infectious Diseases, California 94305, USA
    J Acquir Immune Defic Syndr 23:221-6. 2000
    ..To determine the impact of prior nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy, genotypic resistance, and other variables on response to efavirenz (EFV)- and adefovir dipivoxil (ADV)-based salvage therapy...
  9. pmc High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients
    R W Shafer
    Division of Infectious Diseases and Center for AIDS Research, Stanford University Medical Center, Stanford, California 94305, USA
    J Clin Microbiol 39:1522-9. 2001
    ....
  10. ncbi request reprint Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy
    N Shulman
    Stanford University School of Medicine, Stanford, CA 94305, USA
    AIDS 15:1125-32. 2001
    ..A reversal of phenotypic resistance was seen in patients with NNRTI mutations in the presence of multiple NRTI mutations, but no obvious virologic benefit of this phenomenon was seen in this study...
  11. ncbi request reprint Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy
    N S Shulman
    Division of Infectious Diseases, Stanford University Medical Center, Stanford, California 94305, USA
    J Acquir Immune Defic Syndr 27:377-80. 2001
    ..We conclude that in patients with prior ZDV treatment, those with only one ZDV mutation, particularly at position 70, can still get reasonable virologic activity from d4T. Those with more mutations are not likely to have much benefit...
  12. ncbi request reprint High levels of adherence do not prevent accumulation of HIV drug resistance mutations
    David R Bangsberg
    Epidemiology and Prevention Interventions Center, Division of Infectious Diseases, San Francisco General Hospital, California, USA
    AIDS 17:1925-32. 2003
    ....
  13. ncbi request reprint Prevalence of antiretroviral drug resistance in the HIV-1-infected urban indigent population in San Francisco: a representative study
    M Holodniy
    AIDS Research Center, VA Palo Alto Health Care System, Palo Alto, USA
    Int J STD AIDS 15:543-51. 2004
    ....
  14. doi request reprint Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor
    Philip Grant
    Division of Infectious Diseases and Geographic Medicine, Stanford University, Palo Alto, California 94305 5107, USA
    Clin Infect Dis 48:680-2. 2009
    ....
  15. ncbi request reprint Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: no time to lose
    Philip Grant
    Division of Infectious Diseases and Geographic Medicine, 300 Pasteur Drive, Room S 101, Stanford, CA 94305 5107, USA
    Curr HIV/AIDS Rep 6:63-7. 2009
    ..Initiating ART in the hospitalized patient can be challenging and requires a well-coordinated multidisciplinary team with expertise in ART management...
  16. pmc Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia
    Nancy Shulman
    Stanford University School of Medicine, California, USA
    Antimicrob Agents Chemother 46:3907-16. 2002
    ..The virtual inhibitory quotient, which incorporates both baseline viral resistance and the level of drug exposure in plasma, was superior to either baseline resistance or drug exposure alone in predicting the virologic response...
  17. pmc Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection
    Philip M Grant
    Stanford University, Palo Alto, California, United States of America
    PLoS ONE 5:e11416. 2010
    ..However, few studies are prospective, and no study has evaluated the impact of the timing of ART when allocated randomly during an acute opportunistic infection (OI)...
  18. pmc HIV-1 protease mutations and protease inhibitor cross-resistance
    Soo Yon Rhee
    Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California 94305, USA
    Antimicrob Agents Chemother 54:4253-61. 2010
    ....
  19. pmc Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis
    Eran Bendavid
    Division of General Internal Medicine, Stanford University, Stanford, USA
    AIDS 25:211-20. 2011
    ..the World Health Organization (WHO) recently changed its first-line antiretroviral treatment guidelines in resource-limited settings. The cost-effectiveness of the new guidelines is unknown...
  20. pmc Virologic response to lopinavir-ritonavir-based antiretroviral regimens in a multicenter international clinical cohort: comparison of genotypic interpretation scores
    Philip Grant
    Stanford University, Palo Alto, California, USA
    Antimicrob Agents Chemother 52:4050-6. 2008
    ....
  21. pmc Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAART era
    Leslie Cockerham
    Department of Medicine, University of California, San Francisco, CA, USA
    J Acquir Immune Defic Syndr 53:102-6. 2010
    ..To determine the relationship of HIV infection, demographic, and cardiovascular disease (CVD) risk factors with mortality in the recent highly active antiretroviral therapy era...
  22. pmc Regional adipose tissue and elevations in serum aminotransferases in HIV-infected individuals
    Phyllis C Tien
    Department of Medicine, University of California, San Francisco, CA 94121, USA
    J Acquir Immune Defic Syndr 48:169-76. 2008
    ..Obesity is associated with hepatic steatosis, and ALT is a marker of steatosis in the general population...
  23. pmc Regional adipose tissue and lipid and lipoprotein levels in HIV-infected women
    Judith Currier
    Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA
    J Acquir Immune Defic Syndr 48:35-43. 2008
    ..HIV infection and antiretroviral therapy are associated with dyslipidemia, but the association between regional body fat and lipid levels is not well described...
  24. ncbi request reprint Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients
    Nancy S Shulman
    Stanford University School of Medicine, California 94305, USA
    J Acquir Immune Defic Syndr 31:121-7. 2002
    ..d4T susceptibility greater than 1.4-fold change was associated with failure to achieve significant viral load reduction after 8 weeks of d4T monotherapy...
  25. ncbi request reprint Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine
    Denise Lecossier
    INSERM U552, Hopital Bichat Claude Bernard, Paris, France
    J Acquir Immune Defic Syndr 38:37-42. 2005
    ..These findings support the idea that minority viral populations with distinct resistance genotypes, although undetectable by standard genotyping, can contribute to the failure of salvage regimens...
  26. ncbi request reprint Genotype-phenotype discordance: the evolution in our understanding HIV-1 drug resistance
    Andrew R Zolopa
    AIDS 17:1077-8. 2003
  27. ncbi request reprint Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection
    Thomas B Campbell
    Division of Infectious Diseases, Department of Medicine, University of Colorado Health Sciences Center, Denver 80262, USA
    Clin Infect Dis 41:236-42. 2005
    ..Available data suggest that lamivudine contributes to partial viral suppression, despite the presence of M184V mutations and high-level phenotypic lamivudine resistance...
  28. pmc HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance
    Soo Yon Rhee
    Division of Infectious Diseases, Department of Medicine, Stanford University, CA 94301, USA
    J Infect Dis 192:456-65. 2005
    ..In contrast, nonpolymorphic treatment-associated mutations may be more sensitive and specific markers of transmitted HIV-1 drug resistance...
  29. pmc Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy
    Rami Kantor
    Division of Infectious Diseases and AIDS Research, Stanford University, Stanford, California 94301, USA
    Antimicrob Agents Chemother 46:1086-92. 2002
    ..The persistence of L90M, V82A/F/T, G48V, and I84V during salvage therapy suggests that these mutations play a role in clinical resistance to multiple PIs...
  30. pmc Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments
    Thomas D Wu
    Department of Biochemistry, Stanford University, Stanford, California 94305, USA
    J Virol 77:4836-47. 2003
    ..The presence of mutational clusters provides insight into the complex mutational patterns required for HIV-1 protease inhibitor resistance...
  31. pmc Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors
    Matthew J Gonzales
    Division of Infectious Diseases, Department of Medicine, Stanford University, CA, USA
    AIDS 17:791-9. 2003
    ..To characterize reverse transcriptase (RT) mutations by their association with extent of nucleoside RT inhibitor (NRTI) therapy. To identify mutational clusters in RT sequences from persons receiving multiple NRTI...
  32. pmc N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure
    Yumi Mitsuya
    Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, California 94305, USA
    AIDS Res Hum Retroviruses 22:1300-5. 2006
    ....
  33. pmc Lack of detectable human immunodeficiency virus type 1 superinfection during 1072 person-years of observation
    Matthew J Gonzales
    Department of Medicine Division of Infectious Diseases, Stanford University, Stanford, USA
    J Infect Dis 188:397-405. 2003
    ..Although HIV-1 PR and RT genes from treated persons may become highly divergent, these changes usually are the result of sequence evolution, rather than superinfection...
  34. pmc Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily
    Edward P Acosta
    University of Alabama at Birmingham, Birmingham, Alabama, USA
    Antimicrob Agents Chemother 51:3104-10. 2007
    ..Although safe and generally well tolerated, 300 mg or 400 mg atazanavir administered every 12 h did not maintain adequate plasma exposure when coadministered with rifampin...
  35. pmc The study of fat redistribution and metabolic change in HIV infection (FRAM): methods, design, and sample characteristics
    Phyllis C Tien
    Department of Medicine, School of Medicine, University of California San Francisco, San Francisco, CA, USA
    Am J Epidemiol 163:860-9. 2006
    ..The representativeness of the FRAM sample increases its value as a resource for studies on fat distribution, metabolic changes, and atherosclerosis in HIV infection...
  36. pmc Case files from Stanford University Medical Center: the initial presentation of HIV-1 infection--where public and personal health meet
    Minghsun Liu
    Division of Infectious Diseases, Stanford University Medical Center, Stanford, California, USA
    MedGenMed 8:24. 2006
  37. ncbi request reprint Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers
    Marshall J Glesby
    Weill Medical College of Cornell University, New York, NY 10021, USA
    Clin Pharmacol Ther 78:143-53. 2005
    ..We evaluated potential bidirectional pharmacokinetic interactions between calcium channel blockers and coadministered indinavir and ritonavir...

Research Grants2

  1. Stanford AIDS Clinical Trials Unit
    Andrew Zolopa; Fiscal Year: 2007
    ..Although this working arrangement has been successful for over 10 years, further consolidations and streamlining described here will ensure that the proposed CTU and CRSs will be even more efficient. ADMINISTRATIVE COMPONENT: ..